Autoimmune Disease Prevalence in a Multiple Sclerosis Cohort in Argentina

Farez, Mauricio; Aguirre, María E. Balbuena; Varela, Francisco J.; Kohler, Alejandro; Correale, Jorge

doi:10.1155/2014/828162

Cited by 10 publications

(10 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Autoimmune diseases are a common occurrence in patients in MS, as the present study shows, in agreement with previous reports (9.4%) 5,11 . Our series showed autoimmune thyroiditis as the most frequent concurrent diagnosis (n = 15/635), which was already reported [11][12][13][14][15] (4/155, 20/199, 106/314, 97/815, 53/286), psoriasis 4 (6/24), asthma 16 (8%), type 1 diabetes mellitus 5 (9/245) and inflammatory bowel disease 6 were the most frequently found AID in other cohorts, and were also featured in the present cohort.…”

Section: Discussionsupporting

confidence: 84%

“Multiple sclerosis plus”: Does it influence the disease course?

Seabra

Abreu

Mendonça

et al. 2020

Clinical & Exp Neuroim

View full text Add to dashboard Cite

Objectives:To study the association between multiple sclerosis (MS) and other autoimmune diseases (AID).Methods: From a cohort of 635 patients with MS, 66 patients with an history of AID were selected. Controls, matched 1:1, were chosen from the population of patients with MS without autoimmune comorbidities. Further analysis aimed to compare these groups. Results:The prevalence of comorbid AID in our population was 10.4%. The mean age was 43 ± 13 years; 77% were women. A total of 15 different types of AID were identified, the predominant one was autoimmune thyroiditis (18/66; 27%). In 46% of patients, the AID was diagnosed before, and in 49%, it was diagnosed after the diagnosis of MS. The presence of family history of AID was not associated with the risk of developing AID. Our analysis found no association between the presence of AID and disease activity (new lesions, gadolinium enhancement, mean of annual relapse rate, initiation of a second-line treatment), either when considering each variable individually or within a composite score. The median Extended Disability Status Scale and Multiple Sclerosis Severity Score was 1.5 (interquartile range [IQR] 3.0) and 1.0 (IQR 3.0), respectively, in the AID group, and 1.5 (IQR 3.0) and 2.0 (IQR 3.0), respectively, in the control group, and the difference was not statistically significant. The presence of a concomitant AID influenced therapeutic choice in nine patients. Conclusions:The present study underlines the varied range of AID that might coexist with MS. This common ground does not seem to have a negative effect on the disease course. K E Y W O R D Sautoimmune diseases, demyelinating diseases, immune system diseases, immunomodulation, multiple sclerosis

show abstract

Section: Discussionsupporting

confidence: 84%

“Multiple sclerosis plus”: Does it influence the disease course?

Seabra

Abreu

Mendonça

et al. 2020

Clinical & Exp Neuroim

View full text Add to dashboard Cite

show abstract

“…After deleting duplicate records and screening the abstracts and titles, 70 articles were selected for full‐text assessment. Ultimately, 17 studies 6 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 were included in the meta‐analysis. A flow diagram of the search results and study selection process is shown in Figure 1 .…”

Section: Resultsmentioning

confidence: 99%

Multiple sclerosis and inflammatory bowel disease: A systematic review and meta‐analysis

Wang

Wan

Wang

et al. 2022

Ann Clin Transl Neurol

View full text Add to dashboard Cite

Background Multiple sclerosis (MS) and inflammatory bowel disease (IBD) are two autoimmune diseases that seriously affect patients' quality of life. Previous studies have established an association between MS and IBD, including Crohn's disease (CD) and ulcerative colitis (UC), but the results were inconsistent. The aim of this study was to quantify the prevalences of and the association between MS and IBD. Methods The PubMed, Web of Science, and Embase databases were searched through November 2020 for studies reporting data on MS among patients with IBD and vice versa. The main outcomes were the proportion of MS in patients with IBD and vice versa, as well as the association (risk ratio [RR]) of IBD in MS and that of MS in IBD. Results Based on the analysis of 17 studies, the prevalence of MS in patients with IBD was 0.2% (95% CI 0.1–0.4%), while the prevalence of IBD in patients with MS was 0.6% (95% CI 0.4–0.9%). Patients with MS had a higher prevalence of IBD than controls (RR = 1.53, 95% CI 1.38–1.70, p < 0.00001). There was a similarly high risk of developing CD (RR 1.41, 95% CI 1.14–1.74, p = 0.001) or UC (RR 1.42, 95% CI 1.17–1.71, p = 0.0003) in patients with MS (p for subgroup differences: 0.97). Patients with IBD had a higher prevalence of MS than controls (RR = 1.91, 95% CI 1.06–3.45, p = 0.03). Conclusions Clinicians should be aware of the increased risk of IBD or MS comorbidity during the diagnostic process. Systematic diagnosis and management at an earlier stage are suggested.

show abstract

“…Multiple sclerosis (MS) is an inflammatory disorder of the brain, spinal cord, and optic nerves with unknown etiology arising as a result of complex interactions between genetic and environmental factors [1][2][3]. It affects twice as many women as men and typically develops between the ages of 20 and 40 years (the average age of MS onset is 30 years) [4].…”

Section: Introductionmentioning

confidence: 99%

Sleep Disorders in Multiple Sclerosis. Review

Veauthier

2015

Curr Neurol Neurosci Rep

View full text Add to dashboard Cite

Sleep disorders are common in patients with multiple sclerosis (MS) and play a crucial role in health and quality of life; however, they are often overlooked. The most important sleep disorders in this context are as follows: insomnia, restless legs syndrome, periodic limb movement disorders, and sleep-related breathing disorders (SRBD). It is unclear if MS-related processes (lesions, brain atrophy) can cause symptomatic forms of sleep apnea. MS-related narcolepsy-like symptoms are described in the literature and, in some cases, have resolved with methylprednisolone pulse therapy. Similarly, REM sleep behavior disorder (RBD) is very rare in MS, but it can be an initial sign of MS where cortisone therapy may be helpful and can be taken into account in this specific context. Independent diagnosis and treatment is required for all of the abovementioned conditions. Treating physicians and neurologists should be aware of these comorbidities and initiate specific therapy. Highly fatigued or sleepy MS patients should have polysomnography in order not to overlook these diagnoses.

show abstract

Autoimmune Disease Prevalence in a Multiple Sclerosis Cohort in Argentina

Cited by 10 publications

References 10 publications

“Multiple sclerosis plus”: Does it influence the disease course?

“Multiple sclerosis plus”: Does it influence the disease course?

Multiple sclerosis and inflammatory bowel disease: A systematic review and meta‐analysis

Sleep Disorders in Multiple Sclerosis. Review

Contact Info

Product

Resources

About